AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

The Arrow® Pressure Injectable Midline Catheter with Chlorag+ard® Antimicrobial and Antithrombogenic Technology is indicated for short-term (< 30 days) peripheral access to the venous therapy, blood sampling. infusion, and pressure injection of contrast media. The maximum pressure injector equipment used with the Arrow Antimicrobial and Antithrombogenic Pressure Injectable Midline Catheter may not exceed 300 psi (2068.4kPa). The maximum pressure injection flow rate for the specific lumen being used for pressure injection is printed on the extension line hub.

Chlorag+ard Technology treatment on the external surface of the catheter body as well as the entire fluid pathway of the catheter has been shown to be effective in reducing microbial colonization and thrombus accumulation on catheter surfaces. Antimicrobial and antithrombogenic effectiveness was evaluated using in vitro and in vivo test methods and no correlation between these testing methods and clinical outcome has currently been ascertained. It is not intended to be used for the treatment of existing infections or vein thrombosis.

Device Description

The Arrow Pressure Injectable Midline Catheter with Chlorag ard Antimicrobial and Antithrombogenic Technology is a single use catheter designed to provide short-term peripheral access to the venous system. It consists of a non-tapered, radiopaque polyurethane extruded catheter body with a softer, contoured Blue FlexTip (flexible distal tip). The catheter is available in 4.5 Fr. Single lumen and 5.5 Fr. Double lumen configurations with a usable catheter length of 15 cm. The catheters can be used for the injection of contrast media. The maximum recommended infusion rate is 5 mL/sec. The external catheter body and the entire internal fluid path of the device are treated with a Chlorhexidine-based solution technology. Studies have shown the technology to possess both antimicrobial and antithrombogenic properties.

The catheters will be packaged sterile in kits that will include components to facilitate insertion. The Chlorag+ard technology that is incorporated in the modified device's physical design is the same as the reference device.

AI/ML Overview

The provided text is a 510(k) summary for the "Arrow Pressure Injectable Midline Catheter with Chlorag+ard Antimicrobial and Antithrombogenic Technology." This document is a premarket notification to the FDA to demonstrate that the new device is substantially equivalent to a legally marketed predicate device. It does not describe a study to prove a device meets acceptance criteria for an AI/algorithm-based medical device.

Instead, this document details the substantial equivalence of a physical medical device (a catheter) to existing predicate devices based on design characteristics, materials, and non-clinical performance testing. The "Chlorag+ard Technology" mentioned refers to a coating on the catheter that has antimicrobial and antithrombogenic properties, which were evaluated using in vitro and in vivo test methods. This is not an AI or algorithm.

Therefore, I cannot provide the requested information regarding acceptance criteria and studies for an AI device. The input document is for a physical medical device, not an AI/algorithm-based one.

If you can provide a different document that describes an AI/algorithm-based medical device, I would be happy to then attempt to answer the questions you've posed.

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized representation of three human profiles facing to the right, stacked on top of each other. The profiles are depicted with simple, curved lines. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the emblem.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

August 24, 2016

Arrow International, Inc. (subsidiary of Teleflex Inc.) Ms. Julie Lawson Regulatory Affairs Specialist 2400 Bernville Road Reading, Pennsylvania 19605

Re: K161313

Trade/Device Name: Arrow Pressure Injectable Midline Catheter with Chlorag+arde Antimicrobial and Antithrombogenic Technology Regulation Number: 21 CFR 880.5200 Regulation Name: Intravascular Catheter Regulatory Class: II Product Code: PND Dated: July 22, 2016 Received: July 25, 2016

Dear Ms. Lawson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Tina Kiang

Tina Kiang, Ph.D. Acting Director Division of Anesthesiology, General Hospital, Respiratory, Infection Control, and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.

510(k) Number (if known) K161313

Device Name

  • ARROW Pressure Injectable Midline Catheter with Chlorag+ard Antimicrobial and Antithrombogenic Technology

Indications for Use (Describe)

The Arrow® Pressure Injectable Midline Catheter with Chlorag+ard® Antimicrobial and Antithrombogenic Technology is indicated for short-term (< 30 days) peripheral access to the venous therapy, blood sampling. infusion, and pressure injection of contrast media. The maximum pressure injector equipment used with the Arrow Antimicrobial and Antithrombogenic Pressure Injectable Midline Catheter may not exceed 300 psi (2068.4kPa). The maximum pressure injection flow rate for the specific lumen being used for pressure injection is printed on the extension line hub.

Chlorag+ard Technology treatment on the external surface of the catheter body as well as the entire fluid pathway of the catheter has been shown to be effective in reducing microbial colonization and thrombus accumulation on catheter surfaces. Antimicrobial and antithrombogenic effectiveness was evaluated using in vitro and in vivo test methods and no correlation between these testing methods and clinical outcome has currently been ascertained. It is not intended to be used for the treatment of existing infections or vein thrombosis.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

510(k) SUMMARY

ARROW PRESSURE INJECTABLE MIDLINE CATHETER WITH CHLORAG ARD ANTIMICROBIAL AND ANTITHROMBOGENIC TECHNOLOGY

1. Submitter Information

Name:Arrow International, Inc. (subsidiary of Teleflex Inc.)
Address:2400 Bernville RoadReading, PA 19605-9607
Telephone Number:(610) 378-0131
Contact Person:Julie LawsonRegulatory Affairs Specialist
Telephone Number:(610) 378-0131 Extension 603256
Fax Number:(610) 478-3179
Email:julie.lawson@teleflex.com

Date Prepared: May 9, 2016

2. Device Name

Device Trade Name:Arrow® Pressure Injectable Midline Catheterwith Chlorag+ard® Antimicrobial and AntithrombogenicTechnology
Common Name:Midline Catheter
Regulation Number:21 CFR: 880.5200
Regulation Name:Intravascular Catheter
Product Code:PND

3. Predicate and Reference Devices

Arrow Peripherally Inserted Midline Catheter (K963257) - Predicate

ArrowEvolution™ Pressure Injectable PICC with Chlorag ard Antimicrobial and Antithrombogenic Technology (K112896) - Reference

4. Device Description

The Arrow Pressure Injectable Midline Catheter with Chlorag ard Antimicrobial and Antithrombogenic Technology is a single use catheter designed to provide short-term peripheral access to the venous system. It consists of a non-tapered, radiopaque polyurethane extruded catheter body with a softer, contoured Blue FlexTip (flexible distal tip). The catheter is available in 4.5 Fr. Single lumen and 5.5 Fr. Double lumen configurations with a usable catheter length of 15 cm. The catheters can be used for the injection of contrast media. The maximum recommended infusion rate is 5 mL/sec. The external catheter body and the entire internal fluid path of the device are treated with a Chlorhexidine-based solution

{4}------------------------------------------------

technology. Studies have shown the technology to possess both antimicrobial and antithrombogenic properties.

The catheters will be packaged sterile in kits that will include components to facilitate insertion. The Chlorag+ard technology that is incorporated in the modified device's physical design is the same as the reference device.

5. Indications for Use

The Arrow Pressure Injectable Midline Catheter with Chlorag ard® Antimicrobial and Antithrombogenic Technology is indicated for short-term (< 30 days) peripheral access to the venous system for intravenous therapy, blood sampling, infusion, and pressure injection of contrast media. The maximum pressure injector equipment used with the Arrow Antimicrobial and Antithrombogenic Pressure Injectable Midline Catheter may not exceed 300 psi (2068.4kPa). The maximum pressure injection flow rate for the specific lumen being used for pressure injection is printed on the extension line hub.

Chlorag ard Technology treatment on the external surface of the catheter body as well as the entire fluid pathway of the catheter has been shown to be effective in reducing microbial colonization and thrombus accumulation on catheter surfaces. Antimicrobial and antithrombogenic effectiveness were evaluated using in vitro and in vivo test methods and no correlation between these testing methods and clinical outcome has currently been ascertained. It is not intended to be used for the treatment of existing infections or vein thrombosis or vein thrombosis.

6. Technological Characteristics and Substantial Equivalence

The Arrow Pressure Injectable Midline Catheter with Chlorag+ard Antimicrobial and Antithrombogenic Technology is substantially equivalent to the predicate Arrow Peripherally Inserted Midline Catheter (K963257) in terms of Indications for use. Both the predicate and the subject Indications for Use refer to use for peripheral access to the venous system. The difference in the Indications for use is that the subject Indications for use specifies in more detail the uses for the device and includes the ability to use the device for pressure injection as well as describing the antimicrobial and antithrombogenic properties of the subject catheter. (The predicate device does not contain antimicrobial and antithrombogenic properties.)

The Arrow Pressure Injectable Midline Catheter with Chlorag ard Antimicrobial and Antithrombogenic Technology is substantially equivalent to the reference device, the ArrowEVOLUTION™ Pressure Injectable PICC with Chlorag ard Antimicrobial and Antithrombogenic Technology (K112896) in terms of overall design, manufacturing process, functional performance, and materials of construction. The indications for use for the subject catheter are the same as the reference device (K112896) in all aspects aside from providing central venous access and the ability to use the device

{5}------------------------------------------------

for central venous pressure monitoring. The tip of the reference device (K112896) is intended to terminate in the Superior Vena Cava (central venous system) whereas the tip of the subject device is intended to terminate below the axillary line (venous system).

The same Chlorag+ard Technology treatment that is used for the reference device, the ArrowEVOLUTION™ Pressure Injectable PICC with Chlorag+ard Antimicrobial and Antithrombogenic Technology (K112896) is used for the subject device. The process of application of the Chlorag+ard Technology treatment is also the same as that of the reference device.

DesignCharacteristicPredicate DeviceArrow PeripherallyInserted Midline Catheter(K963257)Reference DeviceAM/AT PICC (K112896)Subject PressureInjectable CG+MIDLINE
Intended UseThe Midline Catheterpermits venous access to theperipheral circulation. Itoffers an alternative methodof intravenous access forselect adult and pediatricpatients.The Pressure InjectablePeripherally InsertedCentral Catheters areintended for short-term orlong-term peripheral accessto the central venoussystem for intravenoustherapy and bloodsampling.The Pressure InjectableMidline Catheters areintended for short-termperipheral access to thevenous system forintravenous therapy andblood sampling.
IndicationsforUseThe Midline Catheterpermits venous access to theperipheral circulation. Itoffers an alternative methodof intravenous access forselect adult and pediatricpatients.The ArrowEVOLUTION™Pressure Injectable PICCwith Chlorag+ardAntimicrobial andAntithrombogenicTechnology is indicated forshort-term or long-termperipheral access to thecentral venous system forintravenous therapy, bloodsampling, infusion, pressureinjection of contrast media,and allows for centralvenous pressuremonitoring. The maximumpressure of pressureinjector equipment usedwith theThe Arrow PressureInjectable MidlineCatheter withChlorag+ardAntimicrobial andAntithrombogenicTechnology is indicatedfor short-term (< 30 days)peripheral access to thevenous system forintravenous therapy,blood sampling, infusion,and pressure injection ofcontrast media. Themaximum pressure ofpressure injectorequipment used with theArrow Antimicrobial andAntithrombogenic
DesignCharacteristicPredicate DeviceArrow PeripherallyInserted Midline Catheter(K963257)Reference DeviceAM/AT PICC (K112896)Subject PressureInjectable CG+MIDLINE
Pressure Injectable PICCmay not exceed 300 psi.Chlorag+ard Technologytreatment on the externalsurface of the catheter bodyas well as the entire fluidpathway of the catheter hasbeen shown to be effectivein reducing microbialcolonization and thrombusaccumulation on cathetersurfaces. Antimicrobialand antithrombogeniceffectiveness wereevaluated using in vitro andin vivo test methods and nocorrelation between thesetesting methods and clinicaloutcome has currently beenascertained. It is notintended to be used for thetreatment of existinginfections or veinthrombosis.Pressure InjectableMidline Catheter may notexceed 300 psi(2068.4kPa). Themaximum pressureinjection flow rate for thespecific lumen being usedfor pressure injection isprinted on the extensionline hub.Chlorag+ard Technologytreatment on the externalsurface of the catheterbody as well as the entirefluid pathway of thecatheter has been shownto be effective inreducing microbialcolonization andthrombus accumulationon catheter surfaces.Antimicrobial andantithrombogeniceffectiveness wereevaluated using in vitroand in vivo test methodsand no correlationbetween these testingmethods and clinicaloutcome has currentlybeen ascertained. It is notintended to be used forthe treatment of existinginfections or veinthrombosis.
Catheter OD3, 4 and 5 Fr4.5 Fr and 5.5 FrSame as reference device:4.5 Fr and 5.5 Fr.
CatheterUsable Length15 cm40, 50, and 55 cmSame as predicate device:15 cm.
DesignCharacteristicPredicate DeviceArrow PeripherallyInserted Midline Catheter(K963257)Reference DeviceAM/AT PICC (K112896)Subject PressureInjectable CG+MIDLINE
Numberof Lumens3, 4 and 5 Fr. - 1 lumen4 and 5 Fr. - 2 lumens4.5 Fr. - 1 lumen5.5 Fr. - 2 lumensSame as reference device:4.5 Fr. - 1 lumen5.5 Fr. - 2 lumens
InternalLumenConfigurationRoundCircle/crescent4.5 Fr. - Round5.5 Fr. - Double DSame as reference device:4.5 Fr. - Round5.5 Fr. - Double D
Catheter TipConfigurationBlunt TipBlue FlexTipSame as reference device:Blue FlexTip
PressureInjectionCapabilitiesNoneDistal lumen – 5 mL/sec,Pressure InjectableProximal lumen – 5mL/sec, Pressure InjectableDistal lumen - 5 mL/sec,Pressure InjectableProximal lumen- Notlabeled for PressureInjection
Chlorhexidine-BasedCoatingPerformanceNoneAntimicrobial EfficacyEffective in reducingmicrobial colonizationAntithrombogenic EfficacyEffective in reducingthrombus accumulationSame as reference device:Antimicrobial EfficacyEffective in reducingmicrobial colonizationAntithrombogenicEfficacyEffective in reducingthrombus accumulation
Catheter BodyMaterialWhite Polyurethane with20% Barium SulfateBlue Polyurethanewith 30% BismuthOxychlorideSame as reference device:Blue Polyurethanewith 30% BismuthOxychloride
Catheter TipMaterialWhite Polyurethane with20% Barium SulfateBlue Polyurethane with30% Bismuth OxychlorideSame as reference device:Blue Polyurethane with30% BismuthOxychloride
JunctureHub MaterialWhite PolyurethaneTransparent Light BluePolyurethaneSame as reference device:Transparent Light BluePolyurethane
Extension LineClear PolyurethaneClear PolyurethaneSame as reference device:
DesignCharacteristicPredicate DeviceArrow PeripherallyInserted Midline Catheter(K963257)Reference DeviceAM/AT PICC (K112896)Subject PressureInjectable CG+MIDLINE
MaterialClear Polyurethane
ExtensionHubMaterialNatural PolyurethaneDistal - Pink PolyurethaneProximal – WhitePolyurethaneSame as reference device:Distal – PinkPolyurethaneProximal – WhitePolyurethane
Printing InkPrinting Ink NT16 Black InkBlack Hot Stamp PrintingFoilPrinting Ink 2405 Black InkSame as reference device:Printing Ink 2405 BlackInk
Safety andPerformanceTestingMechanical testing to:• ISO 10555-1• ISO 10555-3Biocompatibility testingMechanical testing to:• ISO 10555-1• ISO 10555-3Biocompatibility testingSame as both predicateand reference device:Mechanical testing to:• ISO 10555-1• ISO 10555-3Biocompatibility testing

Predicate, Reference and Subject Device Comparison

{6}------------------------------------------------

{7}------------------------------------------------

{8}------------------------------------------------

{9}------------------------------------------------

7. Nonclinical Testing

The following performance testing related to the device changes has been completed to support the substantial equivalence of the subject devices to the predicate and reference devices:

  • O priming volume
  • gravity flow rate O
  • 10 psi pumped flow rate O
  • O rate limited pressure injection
  • pressure limited injection O
  • static burst O
  • mechanical hemolysis O
  • tensile testing (extension line to luer hub) O

The following standards were used in the non-clinical testing listed above:

  • o ASTM F756-08
  • o ISO 10555-1
  • ISO 10555-3 O
  • o ISO 10993-7
  • o ISO 11135

8. Conclusions

The Arrow Pressure Injectable Midline Catheter with Chlorag ard Antimicrobial and Antithrombogenic Technology is the same device as the reference device, the ArrowEVOLUTION Pressure Injectable PICC with Chlorag ard Antimicrobial and Antithrombogenic Technology (K112896) with the exception of usable catheter length, extension line hub design (on proximal lumen of 2 lumen midline catheter) and extension line text. The results of the testing performed have demonstrated that the devices are safe, effective, and perform as intended. The subject device and predicate and reference devices (K963257 and K112896 respectively) have the same insertion site and associated insertion procedure. The final indwelling tip position of the subject and predicate (K963257) device is the same because they are both midline catheters per the proposed indications for use.

In conclusion, the Arrow Pressure Injectable Midline Catheter with Chlorag ard Antimicrobial and Antithrombogenic Technology is substantially equivalent to the predicate Arrow Peripherally Inserted Midline Catheter (K963257) and the reference device, the ArrowEVOLUTION Pressure Injectable PICC with Chlorag ard Antimicrobial and Antithrombogenic Technology (K112896).

§ 880.5200 Intravascular catheter.

(a)
Identification. An intravascular catheter is a device that consists of a slender tube and any necessary connecting fittings and that is inserted into the patient's vascular system for short term use (less than 30 days) to sample blood, monitor blood pressure, or administer fluids intravenously. The device may be constructed of metal, rubber, plastic, or a combination of these materials.(b)
Classification. Class II (performance standards).